Guardant Health (GH)

• Market cap: $5.63B
• 1 day: -4.64%
• 5 days: 2.54%
• 1 month: 10.87%
• 3 months: -5.43%
• 6 months: 104.72%
• Year to date: 48.66%
• 1 year: 162.39%
• 5 years: -38.63%
• 10 years: 46.68%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Employees: 2,021

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

106% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 31

50% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]

29% more capital invested

Capital invested by funds: $2.83B [Q3] → $3.65B (+$819M) [Q4]

10% more funds holding

Funds holding: 267 [Q3] → 295 (+28) [Q4]

7% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 88

5.85% less ownership

Funds ownership: 102.56% [Q3] → 96.71% (-5.85%) [Q4]

48% less call options, than puts

Call options by funds: $29.5M | Put options by funds: $56.8M

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $50 6% upside
• Avg. target: $55 16% upside
• High target: $60 27% upside

12 analyst ratings

• positive: 12 100%
• neutral: 0 0%
• negative: 0 0%

Barclays Luke Sergott 36% 1-year accuracy 21 / 59 met price target	16% upside $55	Overweight Maintained	10 Apr 2025
Mizuho Anthony Petrone 45% 1-year accuracy 10 / 22 met price target	16% upside $55	Outperform Initiated	10 Apr 2025
Stephens & Co. Mason Carrico 15% 1-year accuracy 4 / 26 met price target	16% upside $55	Overweight Reiterated	26 Mar 2025
Morgan Stanley Shannon O'Callaghan 100% 1-year accuracy 1 / 1 met price target	10% upside $52	Overweight Maintained	6 Mar 2025
Piper Sandler David Westenberg 45% 1-year accuracy 19 / 42 met price target	6% upside $50	Overweight Maintained	26 Feb 2025